IN8bio reported preclinical data showing that its pan-γδ T cell engager, INB-619, achieved complete B cell depletion in systemic lupus erythematosus (SLE) donor assays with efficacy comparable to blinatumomab and mosunetuzumab while producing markedly lower IL-6 secretion. The molecule drove robust expansion of both Vδ1+ and Vδ2+ γδ T cell subsets in healthy and SLE donor samples, without activating CD4+ or CD8+ αβ T cells.

The core development is a new entrant in the autoimmune “immune reset” race: a CD19-targeted engager that activates through the γδ T cell receptor rather than CD3. IN8bio presented the results at ACR Convergence 2025, positioning INB-619 as a potential alternative to CD3-engaging bispecifics and an operationally simpler option relative to autologous cell therapies now exploring durable B cell depletion in lupus. The company emphasizes that avoiding CD3 engagement may reduce the risk of cytokine release syndrome and neurotoxicity, a longstanding operational barrier for T cell engagers moving beyond oncology.

Strategically, this is a diversification play that leverages a clear gap in autoimmune development: how to achieve deep, durable B cell clearance without the hospitalization, step-up dosing, intensive monitoring, and rescue-medication logistics that CD3-based engagers and CAR-T often entail. By amplifying endogenous γδ T cells—including tissue-resident Vδ1 cells—INB-619 aims to extend depletion beyond peripheral blood, a limitation of some anti-CD20 regimens. The design also addresses a practical constraint that has hindered γδ-targeted approaches: low baseline γδ counts. If the in vivo expansion observed ex vivo translates clinically, the program could avoid pre-selection based on γδ abundance and broaden site participation.

For trial operators, the immediate implications hinge on whether the safety signal holds in first-in-human studies. A cytokine-sparing profile could eliminate step-up dosing, shorten or avoid inpatient observation, and reduce the dependency on ICU standby and tocilizumab inventory—unlocking broader community rheumatology site participation and lowering startup burden. Early-phase studies will likely center on pharmacokinetics/pharmacodynamics, depth and durability of B-cell depletion across compartments, and flare metrics in high-activity SLE. The selective activation of γδ over αβ T cells could simplify adverse-event monitoring, but regulators will scrutinize infectious risks, hypogammaglobulinemia management, and tissue inflammation given Vδ1’s organ residency. Preclinical translatability is a nontrivial hurdle: γδ biology differs across species, complicating IND-enabling safety packages and dose projection.

The competitive context is moving quickly. CAR-T programs in SLE and other B–cell–mediated diseases are generating remission signals but face scalability, cost, and site-capacity constraints. CD3 bispecifics are being repurposed for autoimmune indications but bring CRS/ICANS baggage and operational complexity. A γδ-TCR–based engager that clears B cells with limited cytokine release would present sponsors and CROs with a more deployable modality—if the depth of depletion rivals the curative-intent ambitions of cellular therapies and if tissue-resident targets are meaningfully affected.

Next, watch for IND timing, dose-selection rationale, and whether IN8bio pursues a basket strategy across B–cell–driven autoimmune conditions or concentrates on SLE to establish proof of concept. Key risks include translational gaps from ex vivo systems, the durability of depletion without continuous dosing, and the balance between immune reset and infection risk requiring chronic IVIG support. Operationally, the presence or absence of step-up dosing and mandated hospitalization will signal the accessibility of this program to non-tertiary sites. If early human data confirm cytokine-sparing engagement with sustained B cell aplasia, expect rapid partnering interest and a reshaping of trial logistics away from oncology-style safety infrastructure toward standard rheumatology workflows.

Source link: https://www.globenewswire.com/news-release/2025/10/27/3174505/0/en/IN8bio-Presents-T-cell-Engager-Data-Demonstrating-Deep-B-Cell-Depletion-for-Autoimmune-Indications.html

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.